entertainment -WSS

entertainment

author：hotspot 2025-09-30 11:57:50 - browse：85167

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Flu vaccine offering decent levels of protection this winter, new data show

explore

WSS

Pfizer highlights cancer drugs it thinks could reignite investor interest

The strategy behind pharma's lawsuits over drug pricing reform

CDC concerned about possible undetected monkeypox spread in U.K.

Biotech companies concerned about China biosecurity crackdown

WATCH: Why do fingernails fall off when they're damaged?

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT's guide to the next generation of CAR

Activists slam private health insurers over coverage restrictions

Colonoscopy at 40? Study finds a possible benefit

At least 13 dead in Texas as scorching temps continue

Paxlovid study fails to answer questions over benefit for broader groups

After affirmative action ruling, medical educators look to 'holistic review'

How to fix the rural physician shortage in the U.S.

Wildfire smoke exposes gaps in outdoor worker protections

Why are elite athletes different? Take a look at their microbes

entertainment

The strategy behind pharma's lawsuits over drug pricing reform

RaDonda Vaught to speak at CommonSpirit event on patient safety

Ask STAT: What do you want to know about ChatGPT in medicine?

International team creates first chimeric human

The battle over the Brookhaven Landfill on Long Island

New guidelines on severe brain injury complicate already difficult decisions

explore

hotspot

hotspot

hotspot